<DOC>
	<DOCNO>NCT02638337</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety ospemifene 60 mg daily ( QD ) compare placebo treatment vulvo-vaginal atrophy ( VVA ) due menopause woman moderate severe vaginal dryness bothersome symptom ( MBS ) VVA .</brief_summary>
	<brief_title>Study Evaluate Ospemifene Patients With Moderate Severe Vaginal Dryness Due Menopause</brief_title>
	<detailed_description />
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Subject postmenopausal . Subject moderate severe vaginal dryness selfreported MBS VVA . Subject clinically significant abnormal finding physical examination . Subject body mass index ( BMI ) equal great 38 kg/m^2 Subject uncontrolled hypertension . Subject clinically significant abnormal finding gynecological examination sign vaginal atrophy . Subject uterine/vaginal bleeding unknown origin . Subject vaginal infection require medication ( may treat eligible study ) .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vulvo-vaginal Atrophy</keyword>
	<keyword>menopause</keyword>
</DOC>